Estrogen and progesterone receptors in melanocytic lesions. Occurrence in patients with dysplastic nevus syndrome
- 1 October 1985
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 121 (10) , 1282-1285
- https://doi.org/10.1001/archderm.121.10.1282
Abstract
Estrogen and progesterone binding studies in a series of 22 melanocytic lesions from 14 patients with the dysplastic nevus syndrome were done using a fluorescent estrogen and progesterone binding technique. Melanocytic lesions from these patients, including primary cutaneous melanomas, dysplastic nevi, and benign nevi, contained large numbers of estrogen and progesterone binding cells. Comparison is made to a series of control intradermal nevi that had little or no detectable estrogen or progesterone binding. Increased hormonal binding, and possibly responsiveness, is seen in melanomas, melanoma precursor lesions such as dysplastic nevi and congenital nevi, as well as benign nevi from patients with the dysplastic nevus syndrome.This publication has 20 references indexed in Scilit:
- Estrogen receptors in patients with malignant melanomaCancer, 1980
- Sex steroid receptor analysis in human melanomaCancer, 1980
- Incidence of estrogen receptor in benign nevi and human malignant melanomaJAMA, 1980
- Activation of nevi in patients with malignant melanomaCancer, 1980
- Familial atypical multiple mole melanoma (FAMMM) syndrome: genetic heterogeneity and malignant melanomaBritish Journal of Cancer, 1980
- Estrogen Receptor Proteins in Diverse Human TumorsArchives of Surgery, 1980
- Familial atypical multiple mole-melanoma syndrome.Journal of Medical Genetics, 1978
- Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'Archives of Dermatology, 1978
- Precursor lesions in familial melanoma. A new genetic preneoplastic syndromeJAMA, 1978
- ŒSTROGEN RECEPTORS IN HUMAN MALIGNANT MELANOMAThe Lancet, 1976